Login
Super Investors NOVO HOLDINGS A/S
NH

NOVO HOLDINGS A/S

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$1.49B
Positions
27
Quarter ended
September 30, 2026
Filed
November 16, 2026

Reported portfolio value by quarter (68 quarters reported)

$2.42B $273M
Q4 09 Q2 13 Q4 16 Q2 20 Q4 23 Q3 26

$281M in Q4 2009 → $1.49B now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
Edgewise Therapeutics Inc 14.6% Unchanged 5,350,000 $217M
AH Asml Holding N V 11.5% Unchanged 94,946 $172M
Brookfield Corp 10.9% Added 28% 4,465,035 $163M
HT Hemab Therapeutics Hldgs Inc 8.7% Unchanged 4,180,550 $129M
AP Avalyn Pharmaceuticals Inc 6.6% Trimmed 11% 3,449,191 $98.3M
Mirum Pharmaceuticals Inc 6.5% Unchanged 1,125,000 $96.2M
Salesforce Inc 6.1% Unchanged 393,187 $90.3M
Enliven Therapeutics Inc 3.1% Unchanged 1,000,000 $45.8M
4M 4d Molecular Therapeutics In 2.9% Trimmed 7.7% 3,000,000 $42.9M
Obsidian Therapeutics Inc 2.9% New 3,123,992 $42.9M
Vaxcyte Inc 2.7% Trimmed 11% 710,000 $40.4M
F& Floor & Decor Hldgs Inc 2.5% Unchanged 797,000 $36.5M
VT Viridian Therapeutics Inc 2.4% Trimmed 18% 1,750,000 $36M
Arrivent Biopharma Inc 2.4% Trimmed 22% 1,175,000 $35.6M
Insmed Inc 2.2% Added 136% 284,425 $32.5M
Pharvaris N V 2.2% Trimmed 27% 1,019,426 $32.3M
CT Celldex Therapeutics Inc New 2.1% Trimmed 7.3% 950,000 $30.8M
AG Alibaba Group Hldg Ltd 1.9% Unchanged 257,327 $27.7M
Xenon Pharmaceuticals Inc 1.6% Added 34% 652,105 $24.3M
SR Scholar Rock Hldg Corp 1.5% New 460,002 $22.2M
Dyne Therapeutics Inc 1.5% Added 43% 1,376,164 $22.2M
Maplight Therapeutics Inc 1.4% Trimmed 43% 2,086,622 $21.3M
Contineum Therapeutics Inc 0.6% New 704,013 $9.45M
Alumis Inc 0.6% Added 14% 1,250,000 $9.24M
BO Bridgebio Oncology Therapeut 0.6% Unchanged 2,250,000 $9.23M
Marqeta Inc 0.1% Trimmed 75% 110,389 $1.88M
Lanzatech Global Inc 0.1% Unchanged 158,148 $903K

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 16, 2026

Company Action Shares changed Value of change % of portfolio
CP Crinetics Pharmaceuticals In Exited −1,320,000 −$49.4M —
Obsidian Therapeutics Inc New +3,123,992 +$42.9M 2.9%
Brookfield Corp Added +968,790 +$35.3M 10.9%
SR Scholar Rock Hldg Corp New +460,002 +$22.2M 1.5%
Insmed Inc Added +163,702 +$18.7M 2.2%
Maplight Therapeutics Inc Trimmed −1,600,000 −$16.3M 1.4%
AP Avalyn Pharmaceuticals Inc Trimmed −434,098 −$12.4M 6.6%
Pharvaris N V Trimmed −380,574 −$12.1M 2.2%
Arrivent Biopharma Inc Trimmed −325,000 −$9.84M 2.4%
Contineum Therapeutics Inc New +704,013 +$9.45M 0.6%

Showing the 10 largest of 18 changes.

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
HT Hemab Therapeutics Hldgs Inc New +4,180,550 +$154M 8.9%
AP Avalyn Pharmaceuticals Inc New +3,883,289 +$128M 7.4%
F& Floor & Decor Hldgs Inc New +797,000 +$47.3M 2.7%
Apogee Therapeutics Inc Exited −450,000 −$37.9M —
Biomarin Pharmaceutical Inc Exited −660,000 −$37.3M —
Alumis Inc New +1,100,000 +$31M 1.8%
Mirum Pharmaceuticals Inc Trimmed −200,000 −$23.4M 7.6%
Dyne Therapeutics Inc New +960,394 +$21.3M 1.2%
Arrivent Biopharma Inc Trimmed −442,142 −$15.4M 3.0%
Enliven Therapeutics Inc Trimmed −280,000 −$14.2M 2.9%

Showing the 10 largest of 19 changes.

Q1 2026

quarter ended March 31, 2026 · filed May 15, 2026

Company Action Shares changed Value of change % of portfolio
Zenas Biopharma Inc Exited −1,450,000 −$52.6M —
Insmed Inc Exited −200,000 −$34.8M —
Xenon Pharmaceuticals Inc New +485,438 +$28.2M 2.3%
AH Asml Holding N V Trimmed −19,000 −$25.1M 10.2%
Salesforce Inc Added +63,000 +$11.8M 5.9%
Apogee Therapeutics Inc Trimmed −120,000 −$10.1M 3.1%
Enliven Therapeutics Inc Trimmed −200,000 −$7.84M 4.1%
Valneva Se Trimmed −1,247,579 −$7.8M 0.5%
VT Viridian Therapeutics Inc Trimmed −380,000 −$7.43M 3.2%
Mirum Pharmaceuticals Inc Added +60,972 +$5.63M 9.9%

Showing the 10 largest of 14 changes.

Q4 2025

quarter ended December 31, 2025 · filed February 17, 2026

Company Action Shares changed Value of change % of portfolio
VI Vanguard Index Fds Exited −1,038,550 −$341M —
Merus N V Exited −750,000 −$70.6M —
Maplight Therapeutics Inc New +3,686,622 +$64.8M 5.0%
Brookfield Corp Added +1,165,415 +$53.5M 12.5%
RP Recursion Pharmaceuticals In Exited −7,929,835 −$38.7M —
AH Asml Holding N V Trimmed −31,890 −$34.1M 9.5%
Zenas Biopharma Inc Trimmed −550,000 −$20M 4.1%
4M 4d Molecular Therapeutics In Added +1,650,737 +$12.4M 2.1%
Apogee Therapeutics Inc Added +70,000 +$5.28M 3.3%
Enliven Therapeutics Inc Added +53,740 +$828K 1.8%

Showing the 10 largest of 12 changes.

Q3 2025

quarter ended September 30, 2025 · filed November 14, 2025

Company Action Shares changed Value of change % of portfolio
Insmed Inc Trimmed −480,000 −$69.1M 1.9%
Blueprint Medicines Corp Exited −264,956 −$34M —
BO Bridgebio Oncology Therapeut New +1,961,317 +$22.7M 1.5%
AG Alibaba Group Hldg Ltd Trimmed −115,000 −$20.6M 3.0%
AH Asml Holding N V Trimmed −20,000 −$19.4M 9.1%
Mirum Pharmaceuticals Inc Trimmed −236,027 −$17.3M 6.0%
Ceribell Inc Exited −900,000 −$16.9M —
RP Recursion Pharmaceuticals In Trimmed −1,735,293 −$8.47M 2.5%
Enliven Therapeutics Inc Added +341,828 +$7M 1.9%
Zenas Biopharma Inc Trimmed −250,000 −$5.55M 2.9%

Showing the 10 largest of 20 changes.

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
Amicus Therapeutics Inc Exited −2,750,000 −$22.4M —
Enliven Therapeutics Inc New +1,084,432 +$21.8M 1.5%
Apogee Therapeutics Inc New +449,392 +$19.5M 1.4%
Salesforce Inc Added +57,386 +$15.6M 6.4%
Verve Therapeutics Inc Exited −3,000,000 −$13.7M —
Valneva Se New +2,375,000 +$13.5M 1.0%
Biomarin Pharmaceutical Inc Added +170,000 +$9.34M 2.6%
CP Crinetics Pharmaceuticals In Added +275,000 +$7.91M 3.1%
Rocket Pharmaceuticals Inc Exited −1,100,000 −$7.34M —
Blueprint Medicines Corp Added +36,152 +$4.63M 2.4%

Showing the 10 largest of 21 changes.

Q1 2025

quarter ended March 31, 2025 · filed May 15, 2025

Company Action Shares changed Value of change % of portfolio
Tempus Ai Inc Exited −4,074,419 −$138M —
Brookfield Corp Trimmed −468,000 −$24.5M 9.3%
Cargo Therapeutics Inc Exited −1,663,724 −$24M —
Ceribell Inc Added +551,191 +$10.6M 1.3%
AG Alibaba Group Hldg Ltd Trimmed −80,000 −$10.6M 3.7%
CP Crinetics Pharmaceuticals In Added +314,785 +$10.6M 3.3%
Edgewise Therapeutics Inc Added +350,000 +$7.7M 9.0%
Arrivent Biopharma Inc Added +351,515 +$6.5M 2.6%
Vaxcyte Inc Added +165,000 +$6.23M 2.6%
Mersana Therapeutics Inc. Exited −4,250,000 −$6.08M —

Showing the 10 largest of 20 changes.

Q4 2024

quarter ended December 31, 2024 · filed February 14, 2025

Company Action Shares changed Value of change % of portfolio
Corcept Therapeutics Inc Exited −2,411,362 −$112M —
RP Recursion Pharmaceuticals In New +10,114,633 +$68.4M 4.1%
Cable One Inc Exited −118,403 −$41.4M —
Brookfield Corp Trimmed −692,400 −$39.8M 9.7%
Alnylam Pharmaceuticals Inc Exited −118,383 −$32.6M —
BA Brookfield Asset Managmt Ltd Exited −627,207 −$29.7M —
Salesforce Inc Trimmed −74,659 −$25M 5.9%
AH Asml Holding N V Added +32,500 +$22.5M 7.0%
Edgewise Therapeutics Inc Trimmed −549,900 −$14.7M 8.1%
Ceribell Inc. New +328,809 +$8.51M 0.5%

Showing the 10 largest of 21 changes.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support